Lee's Pharmaceutical Holdings Limited (HKG:0950)

HKG:0950 Cash Flow Statement

Financials in millions HKD. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	91.94	93.1	16.7	51.28	1,987
Depreciation & Amortization	97.59	99.3	107.95	125.52	126.97
Other Amortization	58.06	48.43	41.55	26.98	19.9
Loss (Gain) From Sale of Assets	0.2	-0.14	-41.63	-0.24	-0.04
Asset Writedown & Restructuring Costs	16.52	25.91	33.31	2.68	235.09
Loss (Gain) From Sale of Investments	-0.35	0.38	1.43	46.36	-2,300
Loss (Gain) on Equity Investments	1.85	0.84	0.87	1.1	3.5
Stock-Based Compensation	0.52	0.41	0.79	12.11	16.89
Provision & Write-off of Bad Debts	0.16	13.7	1.28	-0.26	90.28
Other Operating Activities	10.06	11.07	26.16	33.1	-33.8
Change in Accounts Receivable	-19.22	-82.46	21.09	39.9	-1.95
Change in Inventory	-83.39	-7.22	-61.96	43.28	43.34
Change in Accounts Payable	28.13	69.98	-26.82	39.48	-11.35
Change in Other Net Operating Assets	130.85	-31.28	-10.63	-137.67	34.47
Operating Cash Flow	332.9	242.01	110.08	283.63	210.68
Operating Cash Flow Growth	37.56%	119.85%	-61.19%	34.63%	-3.76%

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-66.63	-43.96	-29.43	-17.46	-50.7
Sale of Property, Plant & Equipment	0.09	0.24	0.11	0.88	0.04
Cash Acquisitions	-	-	-0.02	-	-
Sale (Purchase) of Intangibles	-164.93	-141.54	-110.72	-196.37	-320.03
Investment in Securities	-7	-8.64	-6.7	-45.5	-2.17
Other Investing Activities	2.7	3.66	1.53	2.39	2.58
Investing Cash Flow	-235.77	-190.23	-145.22	-256.05	-370.28

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	271.73	183.92	104.45	60	227.37
Total Debt Issued	271.73	183.92	104.45	60	227.37
Long-Term Debt Repaid	-208.47	-168.21	-80.41	-164.45	-134.02
Total Debt Repaid	-208.47	-168.21	-80.41	-164.45	-134.02
Net Debt Issued (Repaid)	63.26	15.71	24.04	-104.45	93.35
Issuance of Common Stock	-	-	-	-	3.54
Common Dividends Paid	-27.68	-17.67	-10.6	-24.14	-35.92
Financing Cash Flow	35.58	-1.96	13.44	-128.6	60.97

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-4.12	-0.51	-0.08	12.79	0.96
Net Cash Flow	128.6	49.32	-21.77	-88.23	-97.67

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	266.27	198.06	80.65	266.18	159.99
Free Cash Flow Growth	34.44%	145.58%	-69.70%	66.37%	98.70%
Free Cash Flow Margin	18.54%	14.15%	7.66%	21.58%	12.64%
Free Cash Flow Per Share	0.45	0.34	0.14	0.45	0.27
Levered Free Cash Flow	28.64	49.6	-44.97	68.9	-177.85
Unlevered Free Cash Flow	35.42	58.24	-37.92	73.04	-175.1

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	10.02	12.77	10.4	6.24	3.79
Cash Income Tax Paid	15.77	10.61	9.54	-12.88	64.18
Change in Working Capital	56.37	-50.99	-78.33	-15.01	64.52

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 30, 2026

Data Sources Report a data error